135 related articles for article (PubMed ID: 38267640)
1. Translational Potential of a Contrast Agent for FGS Applications in pNETs.
AghaAmiri S; Estrella JS; Vargas SH; Hurd MW; Ghosh SC; Azhdarinia A; Ikoma N
Mol Imaging Biol; 2024 Apr; 26(2):191-194. PubMed ID: 38267640
[No Abstract] [Full Text] [Related]
2. Role of Somatostatin Receptor 2 in Nonfunctional Pancreatic Neuroendocrine Tumors: Clinicopathological Analysis of 223 Cases and Whole Exome Sequencing of a Multifocal Case.
Hu HF; Hu YH; Xu XW; Ye Z; Lou X; Zhang WH; Chen XM; Zhang Y; Yu XJ; Gao HL; Xu JY; Ji SR
Pancreas; 2022 Nov-Dec 01; 51(10):1404-1410. PubMed ID: 37099786
[TBL] [Abstract][Full Text] [Related]
3. Distinguishing pancreatic solid serous cystadenomas from nonfunctional pancreatic neuroendocrine tumors by computed tomography: A propensity score analysis.
Fang X; Jiang H; Cao K; Li J; Liu F; Wang L; Lu J; Shao C; Bian Y
Medicine (Baltimore); 2022 Sep; 101(37):e30523. PubMed ID: 36123910
[TBL] [Abstract][Full Text] [Related]
4. A single-center experience with pancreatic cystic neuroendocrine tumors.
Khalil A; Ewald J; Marchese U; Autret A; Garnier J; Niccoli P; Piana G; Poizat F; Giovannini M; Delpero JR; Turrini O
World J Surg Oncol; 2020 Aug; 18(1):208. PubMed ID: 32799893
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic Neuroendocrine Tumors: Signaling Pathways and Epigenetic Regulation.
Saleh Z; Moccia MC; Ladd Z; Joneja U; Li Y; Spitz F; Hong YK; Gao T
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279330
[TBL] [Abstract][Full Text] [Related]
6. Incidental nonfunctioning pancreatic neuroendocrine tumors: Contrast enhanced ultrasound features in diagnosis1.
Yang D; Wang D; Qiu Y; Tian X; Zuo D; Dong Y; Lou W; Wang W
Clin Hemorheol Microcirc; 2022; 80(4):343-352. PubMed ID: 34602462
[TBL] [Abstract][Full Text] [Related]
7. Radiomics analysis from magnetic resonance imaging in predicting the grade of nonfunctioning pancreatic neuroendocrine tumors: a multicenter study.
Zhu HB; Zhu HT; Jiang L; Nie P; Hu J; Tang W; Zhang XY; Li XT; Yao Q; Sun YS
Eur Radiol; 2024 Jan; 34(1):90-102. PubMed ID: 37552258
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas.
Chen HY; Pan Y; Chen JY; Liu LL; Yang YB; Li K; Yu RS; Shao GL
Eur Radiol; 2022 Dec; 32(12):8317-8325. PubMed ID: 35759016
[TBL] [Abstract][Full Text] [Related]
9. Differential diagnosis between pancreatic solid pseudopapillary tumors and pancreatic neuroendocrine tumors based on contrast enhanced ultrasound imaging features.
Zhang Q; Qiu YJ; Yang DH; Lu XY; Chen S; Dong Y; Wang WP
Clin Hemorheol Microcirc; 2023; 85(4):421-431. PubMed ID: 37718786
[TBL] [Abstract][Full Text] [Related]
10. Endoscopic Ultrasound-Guided Therapies in Patients with Pancreatic Neuroendocrine Tumors.
Morgan AD; Ramai D; Bandaru P; Crino SF; Facciorusso A
Endocr Metab Immune Disord Drug Targets; 2023; 23(11):1355-1358. PubMed ID: 37055906
[TBL] [Abstract][Full Text] [Related]
11. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for prognosis in pancreatic neuroendocrine tumors.
Zhu M; Sorenson KR; Liu R; Gould Rothberg BE; Halfdanarson TR
Endocr Relat Cancer; 2021 Oct; 28(12):773-782. PubMed ID: 34582360
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of Somatostatin Receptor Type 2 Improves 177Lu-DOTATATE Therapy in Receptor-Deficient Pancreatic Neuroendocrine Tumor Model.
Sharma R; Earla B; Baidoo KE; Zeiger MA; Madigan JP; Escorcia FE; Sadowski SM
Mol Cancer Ther; 2023 Sep; 22(9):1052-1062. PubMed ID: 37487000
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features and long-term prognosis of purely cystic pancreatic neuroendocrine tumors: A single-center experience.
Ren SJ; Wang X; Ke NW; Tan QQ; Yang F; Yao WQ; Tan CL; Liu XB
Asian J Surg; 2023 Feb; 46(2):774-779. PubMed ID: 35850904
[TBL] [Abstract][Full Text] [Related]
15. Synchronous Insulinoma and Glucagonoma: A Review of the Literature.
Damaskos C; Dimitroulis D; Garmpi A; Antoniou EA; Kouraklis G; Psilopatis I; Mavri M; Diamantis E; Marinos G; Kyriakos G; Farmaki P; Patsouras A; Kontzoglou K; Garmpis N
In Vivo; 2023; 37(6):2402-2408. PubMed ID: 37905620
[TBL] [Abstract][Full Text] [Related]
16. Genetics of Pancreatic Neuroendocrine Tumors.
Mohindroo C; McAllister F; De Jesus-Acosta A
Hematol Oncol Clin North Am; 2022 Oct; 36(5):1033-1051. PubMed ID: 36154786
[TBL] [Abstract][Full Text] [Related]
17. MK2 Promotes the Development and Progression of Pancreatic Neuroendocrine Tumors Mediated by Macrophages and Metabolomic Factors.
Jacenik D; Lebish EJ; Beswick EJ
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362348
[TBL] [Abstract][Full Text] [Related]
18. Metformin and pancreatic neuroendocrine tumors: A systematic review and meta-analysis.
Cigrovski Berkovic M; Coppola A; Sesa V; Mrzljak A; Lai Q
World J Gastroenterol; 2024 Feb; 30(7):759-769. PubMed ID: 38515954
[TBL] [Abstract][Full Text] [Related]
19. Nonhypervascular pancreatic neuroendocrine tumors: Spectrum of MDCT imaging findings and differentiation from pancreatic ductal adenocarcinoma.
Karmazanovsky G; Belousova E; Schima W; Glotov A; Kalinin D; Kriger A
Eur J Radiol; 2019 Jan; 110():66-73. PubMed ID: 30599875
[TBL] [Abstract][Full Text] [Related]
20. Long-term Follow-up of Small Nonfunctioning Pancreatic Neuroendocrine Tumors Diagnosed Using Endoscopic Ultrasound-guided Fine-needle Aspiration.
Takano Y; Yamawaki M; Noda J; Azami T; Niiya F; Maruoka N; Yamagami T; Norose T; Ohike N; Nagahama M
Intern Med; 2023 Dec; 62(24):3585-3590. PubMed ID: 37081682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
